Ligand Pharmaceuticals (LGND) Accumulated Depreciation & Amortization (2016 - 2024)
Historic Accumulated Depreciation & Amortization for Ligand Pharmaceuticals (LGND) over the last 13 years, with Q4 2024 value amounting to $35.2 million.
- Ligand Pharmaceuticals' Accumulated Depreciation & Amortization fell 351.03% to $35.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $35.2 million, marking a year-over-year decrease of 351.03%. This contributed to the annual value of $35.2 million for FY2024, which is 351.03% down from last year.
- Latest data reveals that Ligand Pharmaceuticals reported Accumulated Depreciation & Amortization of $35.2 million as of Q4 2024, which was down 351.03% from $36.5 million recorded in Q4 2023.
- Ligand Pharmaceuticals' 5-year Accumulated Depreciation & Amortization high stood at $51.5 million for Q4 2022, and its period low was $25.7 million during Q4 2020.
- For the 5-year period, Ligand Pharmaceuticals' Accumulated Depreciation & Amortization averaged around $40.0 million, with its median value being $36.5 million (2023).
- Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first surged by 9878.95% in 2021, then crashed by 2913.22% in 2023.
- Quarter analysis of 5 years shows Ligand Pharmaceuticals' Accumulated Depreciation & Amortization stood at $25.7 million in 2020, then skyrocketed by 98.79% to $51.1 million in 2021, then increased by 0.91% to $51.5 million in 2022, then dropped by 29.13% to $36.5 million in 2023, then fell by 3.51% to $35.2 million in 2024.
- Its last three reported values are $35.2 million in Q4 2024, $36.5 million for Q4 2023, and $51.5 million during Q4 2022.